Your browser doesn't support javascript.
loading
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
Solforosi, Laura; Kuipers, Harmjan; Jongeneelen, Mandy; Rosendahl Huber, Sietske K; van der Lubbe, Joan E M; Dekking, Liesbeth; Czapska-Casey, Dominika N; Izquierdo Gil, Ana; Baert, Miranda R M; Drijver, Joke; Vaneman, Joost; van Huizen, Ella; Choi, Ying; Vreugdenhil, Jessica; Kroos, Sanne; de Wilde, Adriaan H; Kourkouta, Eleni; Custers, Jerome; van der Vlugt, Remko; Veldman, Daniel; Huizingh, Jeroen; Kaszas, Krisztian; Dalebout, Tim J; Myeni, Sebenzile K; Kikkert, Marjolein; Snijder, Eric J; Barouch, Dan H; Böszörményi, Kinga P; Stammes, Marieke A; Kondova, Ivanela; Verschoor, Ernst J; Verstrepen, Babs E; Koopman, Gerrit; Mooij, Petra; Bogers, Willy M J M; van Heerden, Marjolein; Muchene, Leacky; Tolboom, Jeroen T B M; Roozendaal, Ramon; Brandenburg, Boerries; Schuitemaker, Hanneke; Wegmann, Frank; Zahn, Roland C.
Afiliación
  • Solforosi L; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Kuipers H; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Jongeneelen M; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Rosendahl Huber SK; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • van der Lubbe JEM; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Dekking L; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Czapska-Casey DN; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Izquierdo Gil A; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Baert MRM; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Drijver J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Vaneman J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • van Huizen E; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Choi Y; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Vreugdenhil J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Kroos S; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • de Wilde AH; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Kourkouta E; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Custers J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • van der Vlugt R; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Veldman D; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Huizingh J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Kaszas K; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Dalebout TJ; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands.
  • Myeni SK; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands.
  • Kikkert M; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands.
  • Snijder EJ; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands.
  • Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Böszörményi KP; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • Stammes MA; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • Kondova I; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • Verschoor EJ; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • Verstrepen BE; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • Koopman G; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • Mooij P; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • Bogers WMJM; Biomedical Primate Research Centre, Rijswijk, Netherlands.
  • van Heerden M; Non-Clinical Safety Toxicology/Pathology, Janssen Research and Development, Beerse, Belgium.
  • Muchene L; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Tolboom JTBM; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Roozendaal R; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Brandenburg B; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Schuitemaker H; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Wegmann F; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
  • Zahn RC; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
J Exp Med ; 218(7)2021 07 05.
Article en En | MEDLINE | ID: mdl-33909009
Safe and effective coronavirus disease-19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1-skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Envejecimiento / Adenoviridae / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Animals Idioma: En Revista: J Exp Med Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Envejecimiento / Adenoviridae / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Animals Idioma: En Revista: J Exp Med Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos